A multi-center phase III study of carboplatin/paclitaxel versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer

8521 Background: Previous studies have reported that adjuvant chemotherapy provides a survival benefit in patients with resected non-small cell lung cancer (NSCLC). In Japan, uracil-tegafur (UFT) has been used for patients with completely resected NSCLC. We conducted a phase III study of carboplatin/paclitaxel versus UFT as the adjuvant chemotherapy in resected NSCLC. Methods: The patients with pathological stage IB-IIIA NSCLC, who underwent...